Discovering drugs to treat coronavirus disease 2019 (COVID-19).
By Liying Dong, Shasha Hu, Jianjun Gao. Drug Discoveries & Therapeutics, 2020
1,278 citations recorded by the source corpus.
The SARS-CoV-2 virus emerged in December 2019 and then spread rapidly worldwide, particularly to China, Japan, and South Korea. Scientists are endeavoring to find antivirals specific to the virus. Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far. This article summarizes agents with potential efficacy against SARS-CoV-2.
Subfields: Infectious Diseases, Neurology
View Paper: https://www.semanticscholar.org/paper/567ba4bdc6dabcc6a0dd9fb68899f7edb6d4238b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Neurology
Citations in the corpus
- SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues (2020, neutral): “Clinical therapy using approved IFNs has been attempted for SARS-CoV, MERS-CoV, and SARS-CoV-2 in the absence of a controlled trial to mixed effect, resulting in anecdotal evidence suggesting either rapid improvement or worsening of symptoms (Dong et al., 2020b; Lei et al., 2020; Li and De Clercq, 2”
- COVID-19: Transmission, prevention, and potential therapeutic opportunities (2020, neutral): “(BARI-COVID) NCT04320277 Recruiting Italy Adaptive COVID-19 Treatment Trial (ACTT) Drug: Remdesivir NCT04280705 Recruiting United States Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu Drug: N-acetylcysteine + Fuzheng Huayu Tablet, N-acetylcysteine + Placebo NCT04279197”
- The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro (2020, positive): “This Brief Report raises the possibility that ivermectin could be a useful antiviral to limit SARS-CoV-2, in similar fashion to those already reported (Dong et al., 2020; Elfiky, 2020; Gordon et al., 2020; Li and De Clercq, 2020; Wang et al., 2020) ; until one of these is proven to be beneficial in ”
- The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China (2020, background): “Guidelines (version 6) for treatment of COVID-19 recommends chloroquine phosphate is orally administered at a dose of 500 mg (300 mg for chloroquine) for adults, 2 times/ day (no more than 10 days) [39].”
- SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective (2020, background): “Due to the safety profile for these drugs (approved by the FDA before for other viruses or microbes), it can be successful candidates as anti-COVID-19 possible drugs as reported earlier (AlTawfiq et al., 2020; Dong et al., 2020; Elfiky, 2020a, 2020b; Lythgoe & Middleton, 2020).”
- Depression and anxiety among university students during the COVID-19 pandemic in Bangladesh: A web-based cross-sectional survey (2020, methodology): “Following the detection of first COVID-19 case on March 8, 2020 [6], Bangladesh like many other countries put the lockdown strategy into effect on March 26, 2020, to ensure ‘social distance’ through ‘home quarantine’ to curb the ‘spread’ among its population [7–9], since a precise treatment or vacci”
- Psychometric Validation of the Bangla Fear of COVID-19 Scale: Confirmatory Factor Analysis and Rasch Analysis (2020, background): “To date, the scientific community has described the clinical course of COVID-19, counted cases and monitored its spread country-by-country, and has been trying to develop a vaccine (Dong et al. 2020; Wang et al. 2020).”